From innovation to molecular excellence

Pioneering molecular diagnostics to ensure accuracy, reliability, and innnovation in PCR testing

THE HISTORY OF VIRCELL

Founded in 1991, Vircell has been at the forefront of infectious disease diagnostics, offering solutions across microbiology, immunology, and molecular diagnostics. With a strong international presence in over 95 countries, Vircell has built a reputation for delivering high-quality diagnostic tools that enhance laboratory efficiency and accuracy.

Recognizing the growing need for standardized molecular controls, Vircell launched its Molecular Diagnostics Division in 2002, dedicated to developing PCR-based solutions to support the increasing demand for accurate nucleic acid testing. This initiative paved the way for AMPLIRUN®, a pioneering molecular control solution.

THE BIRTH OF AMPLIRUN®, A TRUSTED MOLECULAR CONTROL SOLUTION

As molecular diagnostics advanced, the demand for reliable and high-quality molecular controls became increasingly critical. In response to this need, Vircell developed AMPLIRUN®, a comprehensive molecular control designed to enhance PCR assay performance and optimize laboratory workflows.

Quantified Third-Party Molecular Controls AMPLIRUN®
Provides pre-quantified molecular standards, ensuring reproducibility and precise PCR results, making it an essential tool for assay validation and quality control.

Broad Compatibility Across qPCR Platforms
AMPLIRUN® is designed to be highly versatile, supporting a wide range of real-time PCR instruments and applications in molecular diagnostics.

Comprehensive Pathogen Coverage
With validated controls for bacteria, viruses, and parasites, AMPLIRUN® supports reliable detection of infectious diseases, ensuring consistent performance in molecular laboratories worldwide.

Lyophilized Format for Maximum Stability
The freeze-dried formulation guarantees long-term stability, reducing the need for cold-chain transport and simplifying storage conditions.

Scientific Research and Publications

Evaluation of real-time NASBA assay for the detection of SARS-CoV-2 compared with real-time PCR

https://pmc.ncbi.nlm.nih.gov/articles/PMC9170118/

This study introduces a real-time NASBA assay as a sensitive and specific alternative to PCR for SARS-CoV-2 detection. It enables isothermal amplification without thermocyclers, making it suitable for resource-limited settings. The assay shows high clinical sensitivity (97.64%) and performance comparable to FDA-approved methods.

Mass Molecular Testing for COVID-19 Using NGS-Based Technology and a Highly Scalable Workflow

https://www.nature.com/articles/s41598-021-86498-3

This research explores a cost-effective,NGS-based COVID-19 diagnostic method capable of processing up to 6,144 samples per run. The study highlights its scalability, high accuracy (98% for low CT values), and its potential to alleviate testing bottlenecks caused by RT-PCR supply shortages.

Participation in national quality control program (SEIMC, Spain)

https://www.seimc.org/contenidos/ccs/analisisderesultados/2024/ccs-ar-2024C1-1-Virologia.pdf

This virology study evaluates the external control results of plasma simples provided by Vircell. The findings confirm the stability and homogeneity of the simples, validated by expert laboratories using high-sensitivity diagnostic methods, ensuring the reliability of the program.

Evaluation of real-time NASBA assay for the detection of SARS-CoV-2 compared with real-time PCR

https://pmc.ncbi.nlm.nih.gov/articles/PMC9170118/

This study introduces a real-time NASBA assay as a sensitive and specific alternative to PCR for SARS-CoV-2 detection. It enables isothermal amplification without thermocyclers, making it suitable for resource-limited settings. The assay shows high clinical sensitivity (97.64%) and performance comparable to FDA-approved methods.

Mass Molecular Testing for COVID-19 Using NGS-Based Technology and a Highly Scalable Workflow

https://www.nature.com/articles/s41598-021-86498-3

This research explores a cost-effective,NGS-based COVID-19 diagnostic method capable of processing up to 6,144 samples per run. The study highlights its scalability, high accuracy (98% for low CT values), and its potential to alleviate testing bottlenecks caused by RT-PCR supply shortages.

Participation in national quality control program (SEIMC, Spain)

https://www.seimc.org/contenidos/ccs/analisisderesultados/2024/ccs-ar-2024C1-1-Virologia.pdf

This virology study evaluates the external control results of plasma simples provided by Vircell. The findings confirm the stability and homogeneity of the simples, validated by expert laboratories using high-sensitivity diagnostic methods, ensuring the reliability of the program.

Evaluation of real-time NASBA assay for the detection of SARS-CoV-2 compared with real-time PCR

https://pmc.ncbi.nlm.nih.gov/articles/PMC9170118/

This study introduces a real-time NASBA assay as a sensitive and specific alternative to PCR for SARS-CoV-2 detection. It enables isothermal amplification without thermocyclers, making it suitable for resource-limited settings. The assay shows high clinical sensitivity (97.64%) and performance comparable to FDA-approved methods.

Mass Molecular Testing for COVID-19 Using NGS-Based Technology and a Highly Scalable Workflow

https://www.nature.com/articles/s41598-021-86498-3

This research explores a cost-effective,NGS-based COVID-19 diagnostic method capable of processing up to 6,144 samples per run. The study highlights its scalability, high accuracy (98% for low CT values), and its potential to alleviate testing bottlenecks caused by RT-PCR supply shortages.

Participation in national quality control program (SEIMC, Spain)

https://www.seimc.org/contenidos/ccs/analisisderesultados/2024/ccs-ar-2024C1-1-Virologia.pdf

This virology study evaluates the external control results of plasma simples provided by Vircell. The findings confirm the stability and homogeneity of the simples, validated by expert laboratories using high-sensitivity diagnostic methods, ensuring the reliability of the program.